- Home
- ESPR vs FTHY Comparison
ESPR vs FTHY Comparison
Compare ESPR & FTHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- FTHY
- Stock Information
- Founded
- ESPR 2008
- FTHY 2020
- Country
- ESPR United States
- FTHY United States
- Employees
- ESPR N/A
- FTHY N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- FTHY Investment Managers
- Sector
- ESPR Health Care
- FTHY Finance
- Exchange
- ESPR Nasdaq
- FTHY Nasdaq
- Market Cap
- ESPR 660.1M
- FTHY 539.8M
- IPO Year
- ESPR 2013
- FTHY N/A
- Fundamental
- Price
- ESPR $3.68
- FTHY $14.13
- Analyst Decision
- ESPR Buy
- FTHY
- Analyst Count
- ESPR 7
- FTHY 0
- Target Price
- ESPR $6.86
- FTHY N/A
- AVG Volume (30 Days)
- ESPR 7.0M
- FTHY 176.7K
- Earning Date
- ESPR 11-06-2025
- FTHY 01-01-0001
- Dividend Yield
- ESPR N/A
- FTHY 10.93%
- EPS Growth
- ESPR N/A
- FTHY N/A
- EPS
- ESPR N/A
- FTHY N/A
- Revenue
- ESPR $303,802,000.00
- FTHY N/A
- Revenue This Year
- ESPR $18.83
- FTHY N/A
- Revenue Next Year
- ESPR N/A
- FTHY N/A
- P/E Ratio
- ESPR N/A
- FTHY N/A
- Revenue Growth
- ESPR 2.83
- FTHY N/A
- 52 Week Low
- ESPR $0.69
- FTHY $12.66
- 52 Week High
- ESPR $3.94
- FTHY $14.74
- Technical
- Relative Strength Index (RSI)
- ESPR 71.27
- FTHY 53.50
- Support Level
- ESPR $2.66
- FTHY $13.82
- Resistance Level
- ESPR $3.26
- FTHY $14.21
- Average True Range (ATR)
- ESPR 0.23
- FTHY 0.10
- MACD
- ESPR 0.05
- FTHY 0.01
- Stochastic Oscillator
- ESPR 94.43
- FTHY 83.78
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About FTHY First Trust High Yield Opportunities 2027 Term Fund
FIRST TRUST HIGH YIELD OPPORTUNITIES 2027 TERM FUND is a diversified, closed-end management investment company. The investment objective of the fund is to provide current income. The fund invests a majority of its managed assets in high-yield debt securities of any maturity that are rated below investment grade at the time of purchase or unrated securities. Its investment portfolio comprises corporate bonds and notes, senior floating-rate loan interests, foreign corporate bonds and notes, money market funds, and other instruments across various industries.